Sign up to read this article for FREE!
After signing up, you'll start to receive regular news updates from us.
Polyphor Ltd and Axxam SpA Announce Ion Channel Collaboration
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Polyphor Ltd and Axxam SpA have announced a joint discovery agreement with a synergistic combination of their discovery platforms.
Under the terms of the collaboration the two companies will work together to discover and develop innovative drug candidates for selected therapeutic areas such as pain, inflammation, and metabolic disorders.
Axxam will apply its expertise and outstanding Hit Discovery platforms and capabilities, and Polyphor will provide its unique, proprietary PEM finder® library for screening together with its expertise in medicinal chemistry, drug discovery and development. The collaboration comprises several discovery programs addressing attractive ion channel based targets.
Under the terms of the collaboration the two companies will work together to discover and develop innovative drug candidates for selected therapeutic areas such as pain, inflammation, and metabolic disorders.
Axxam will apply its expertise and outstanding Hit Discovery platforms and capabilities, and Polyphor will provide its unique, proprietary PEM finder® library for screening together with its expertise in medicinal chemistry, drug discovery and development. The collaboration comprises several discovery programs addressing attractive ion channel based targets.
